An Updated Meta-Analysis on the Association of MDM2 SNP309 Polymorphism with Colorectal Cancer Risk

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Qin, Xue ^a   Peng, Qiliu ^a   Tang, Weizhong ^a   Lao, Xianjun ^a   Chen, Zhiping ^b   Lai, Hao ^b   Deng, Yan ^a   Mo, Cuiju ^a   Sui, Jingzhe ^a   Wu, Junrong ^a   Zhai, Limin ^a   Yang, Shi ^a   Li, Shan ^a   Zhao, Jinmin ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MOUSE DOUBLE MINUTE 2 GENE; NEGRO; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; GENETIC ASSOCIATION STUDIES; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84884764409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076031     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300. doi:10.3322/caac.20073. PubMed: 20610543.
2. Ferlay J, Parkin DM, Steliarova-Foucher E, (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781. doi:10.1016/j.ejca.2009.12.014. PubMed: 20116997.
3. Sung JJ, Lau JY, Goh KL, Leung WK, (2005) Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 6: 871-876. doi:10.1016/S1470-2045(05)70422-8. PubMed: 16257795.
4. Zhao P, Dai M, Chen W, Li N, (2010) Cancer trends in China. Jpn J Clin Oncol 40: 281-285. doi:10.1093/jjco/hyp187. PubMed: 20085904.
5. Le Marchand L, Donlon T, Seifried A, Wilkens LR, (2002) Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1019-1024. PubMed: 12376502.
6. Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Sébille V, et al. (2007) Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev 16: 1460-1467. doi:10.1158/1055-9965.EPI-07-0236. PubMed: 17627011.
7. Wu H, Leng RP, (2011) UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 10: 1912-1915. doi:10.4161/cc.10.12.15882. PubMed: 21558803.
8. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, et al. (2010) The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982-989. doi:10.1038/nsmb.1872. PubMed: 20639885.
9. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602. doi:10.1016/j.cell.2004.11.022. PubMed: 15550242.
10. Levav-Cohen Y, Haupt S, Haupt Y, (2005) Mdm2 in growth signaling and cancer. Growth Factors 23: 183-192. doi:10.1080/08977190500196218. PubMed: 16243710.
11. Fang F, Yu XJ, Yu L, Yao L, (2011) MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol 28: 981-985. doi:10.1007/s12032-010-9577-1. PubMed: 20503107.
12. Cao X, Zhang T, Zhao Z, Zhao T, (2012) MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol 31: 355-359. doi:10.1089/dna.2011.1338. PubMed: 21770737.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012. doi:10.1001/jama.283.15.2008. PubMed: 10789670.
14. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162: 201-211. doi:10.1093/aje/kwi184. PubMed: 15987731.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. doi:10.1136/bmj.327.7414.557. PubMed: 12958120.
16. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. doi:10.1002/sim.1186. PubMed: 12111919.
17. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. doi:10.1016/0197-2456(86)90046-2. PubMed: 3802833.
18. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748. PubMed: 13655060.
19. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi:10.1136/bmj.315.7109.629. PubMed: 9310563.
20. Duval S, Tweedie R, (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463. doi:10.1111/j.0006-341X.2000.00455.x. PubMed: 10877304.
21. Chaar I, Amara S, Khiari M, Ounissi D, Dhraif M, et al. (2013) Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population. Appl Immunohistochem Mol Morphol 21: 228-236. PubMed: 22914606.
22. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, et al. (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43: 950-952. doi:10.1136/jmg.2006.043539. PubMed: 16825430.
23. Khan SA, Idrees K, Forslund A, Zeng Z, Rosenberg S, et al. (2008) Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. J Surg Oncol 97: 621-625. doi:10.1002/jso.20996. PubMed: 18381604.
24. Sugano N, Suda T, Godai TI, Tsuchida K, Shiozawa M, et al. (2010) MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. Genes Chromosomes Cancer 49: 620-629. PubMed: 20461754.
25. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, et al. (2005) The MDM2 promoter polymorphism SNP309T-- G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42: 694-698. doi:10.1136/jmg.2005.031260. PubMed: 16141004.
26. Sotamaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, et al. (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11: 6840-6844. doi:10.1158/1078-0432.CCR-05-1139. PubMed: 16203772.
27. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, et al. (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98: 285-288. doi:10.1093/jnci/djj054. PubMed: 16478747.
28. Alazzouzi H, Suriano G, Guerra A, Plaja A, Espín E, et al. (2007) Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet 44: 75-80. doi:10.1136/jmg.2007.049049. PubMed: 16825434.
29. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120: 563-565. doi:10.1002/ijc.22339. PubMed: 17096342.
30. Liu JN, Zhang XM, Guo YL, Sun T, Lin DX, et al. (2008) [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population]. Zhonghua Zhong Liu Za Zhi 30: 335-338. PubMed: 18953830.
31. Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, et al. (2011) TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Jpn J Clin Oncol 41: 232-238. doi:10.1093/jjco/hyq200. PubMed: 21051533.
32. Chen YL, Chang YS, Chang JG, Wu SM, (2009) Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem 394: 1291-1297. doi:10.1007/s00216-008-2416-y. PubMed: 19015838.
33. Zhang Y, Liu L, Tang Y, Chen C, Wang Q, et al. (2012) Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study. Mol Biol Rep 39: 9661-9668. doi:10.1007/s11033-012-1831-5. PubMed: 22744426.
34. Chaar I, Arfaoui TA, El Amine el HO, Mahmoud LB, Khiari M, et al. (2012) Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population. Eur J Gastroenterol Hepatol 24: 320-327. doi:10.1097/MEG.0b013e32834bdf84. PubMed: 22266832.
35. Tuna G, Kucukhuseyin O, Arikan S, Kaytan Saglam E, Guler E, et al. (2013) Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G Gene Variants Act on Colorectal Cancer Development or Progression? DNA Cell Biol 32: 400-408.
36. Jin M, Zhang S, Zhang Y, Liu B, Wu Y, et al. (2013) Interaction analysis of P53 Pathway gene polymorphisms and colorectal cancer risk. Chin J Dig 32: 703-706.
37. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC, (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ: pp. 247-270. PubMed: 15055300.
38. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533. doi:10.1136/jmg.2005.037952. PubMed: 16258005.
39. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, et al. (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15: 110-114. doi:10.1038/sj.ejhg.5201715. PubMed: 17003841.
40. Lind H, Zienolddiny S, Ekstrøm PO, Skaug V, Haugen A, (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119: 718-721. doi:10.1002/ijc.21872. PubMed: 16496380.
41. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, et al. (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24: 4434-4440. doi:10.1200/JCO.2005.04.1459. PubMed: 16983111.
42. Mitchell AA, Cutler DJ, Chakravarti A, (2003) Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. Am J Hum Genet 72: 598-610. doi:10.1086/368203. PubMed: 12587097.
43. Hosking L, Lumsden S, Lewis K, Yeo A, McCarthy L, et al. (2004) Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet 12: 395-399. doi:10.1038/sj.ejhg.5201164. PubMed: 14872201.
44. Salanti G, Amountza G, Ntzani EE, Ioannidis JP, (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 13: 840-848. doi:10.1038/sj.ejhg.5201410. PubMed: 15827565.
45. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP, (2006) Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 163: 300-309. PubMed: 16410351.
46. Bogush TA, Dudko EA, Beme AA, Bogush EA, Kim AI, et al. (2010) Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc) 75: 1421-1427. doi:10.1134/S0006297910120011. PubMed: 21314611.
47. Verma MK, Miki Y, Sasano H, (2011) Sex steroid receptors in human lung diseases. J Steroid Biochem Mol Biol 127: 216-222. doi:10.1016/j.jsbmb.2011.07.013. PubMed: 21856418.
48. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J, (2011) A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res 13: R3. doi:10.1186/bcr2955. PubMed: 21223569.
49. Gu L, Findley HW, Zhou M, (2002) MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99: 3367-3375. doi:10.1182/blood.V99.9.3367. PubMed: 11964305.
50. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, et al. (2007) A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 67: 2757-2765. doi:10.1158/0008-5472.CAN-06-2656. PubMed: 17363597.
51. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, et al. (2004) Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 88: 113-122. doi:10.1016/j.jsbmb.2003.11.008. PubMed: 15084343.
52. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110. doi:10.1158/0008-5472.CAN-06-0180. PubMed: 16707433.
53. Ioannidis JP, Patsopoulos NA, Evangelou E, (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914-916. doi:10.1136/bmj.39343.408449.80. PubMed: 17974687.